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Background: Migraine, a common chronic-intermittent disorder among reproductive age women, has emerged
as a novel risk factor for adverse perinatal outcomes. Diagnostic reliability of self-report of physician-diagnosed
migraine has not been investigated in pregnancy cohort studies. We investigated agreement of self-report of
physician-diagnosed migraine with the diagnostic criteria promoted by the International Classification of Headache
Disorders, 2nd edition (ICHD-II).
Methods: The cross-sectional study was conducted among 500 women who provided information on a detailed
migraine questionnaire that allowed us to apply all ICHD-II diagnostic criteria.
Results: Approximately 92% of women reporting a diagnosis of migraine had the diagnosis between the ages of
11 and 40 years (<10 years 6.8%; 11–20 years 38.8%; 21–30 years 42.7%; 31–40 years 10.7%; and >40 years 1.0%).
We confirmed self-reported migraine in 81.6% of women when applying the ICHD-II criteria for definitive migraine
(63.1%) and probable migraine (18.5%).
Conclusion: There is good agreement between self-reported migraine and ICHD-II-based migraine classification in
this pregnancy cohort. We demonstrate the feasibility of using questionnaire-based migraine assessment according to
full ICHD-II criteria in epidemiological studies of pregnant women.
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Migraine, a common chronic-intermittent neurovascular
headache disorder, is ranked among the world’s twenty
most disabling medical conditions by the World Health
Organization [1]. Migraine is characterized by episodic
severe headache accompanied by autonomic nervous sys-
tem dysfunction. Women are more commonly affected
than men, with reported lifetime prevalence estimates
of 16-32% for women and 6-9% for men [2-6]. Migraine
risk varies considerably across the life course. The preva-
lence of migraine in women rises after the average age of* Correspondence: Chun-fang.Qiu@Swedish.org
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reproduction in any medium, provided the ormenarche, and peaks before the average age of menopause
[7]. Thus migraines are most prevalent among women in
their childbearing years.
Migraine has emerged as a novel risk factor for adverse
perinatal outcomes including hypertensive disorders of
pregnancy [8,9], preterm birth [10] and placental abrup-
tion [11]. Most prior epidemiologic studies have relied
on self-report of physician-diagnosed migraine as a means
for classifying pregnant women with a history of migraine.
Data from the Women’s Health Study (a study of women
aged ≥ 45 years) showed very good agreement between
self-reported migraine and ICHD-II-based diagnosed mi-
graine. The investigators confirmed self-reported migraine
in > 87% of women when applying the International Clas-
sification of Headache Disorders 2004 criteria (ICHD-II). This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(16.2%) without aura [12]. We are unaware of studies
that investigated diagnostic reliability (commonly measured
using inter-rater agreement) of self-report of physician-
diagnosed migraine in pregnancy cohort studies.
In a cross-sectional study, we investigated 500 pregnant
women who provided information on a detailed migraine
questionnaire that allowed us to apply ICHD-II diagnostic
criteria, promoted by International Headache Society (IHS),
and examined the agreement of self-reported physician
diagnosis of migraine with migraine determined using
the ICHD-II diagnostic criteria (“golden standard”) in
this report.
Methods
Study participants were pregnant women attending pre-
natal care at clinics affiliated with Swedish Medical Center
in Seattle, Washington and enrolled in the Migraine and
Pregnancy Study, a pregnancy cohort study designed to
investigate the relationship between migraine, headache
symptoms before and during pregnancy, and the risk of
preeclampsia [13]. The study population for this report
is from the first 500 participants who were enrolled
(consecutively) and were interviewed during the period
of April 2009 and December 2010. Women were ineli-
gible if they initiated prenatal care after 20 weeks gesta-
tion, were younger than 18 years of age, did not speak
and read English, did not plan to carry the pregnancy to
term, or did not plan to deliver at Swedish Medical Cen-
ter. Participants completed a questionnaire administered
by trained interviewers (supervised by neurologist and
maternal fetal medicine clinicians) at enrollment. Partici-
pants were asked to provide information pertaining to
their medical history, pre-pregnancy weight, general
health, pregnancy-related symptoms, socio-demographic,
and lifestyle characteristics. The interview included a
structured migraine assessment questionnaire (adapted
from the deCODE Genetics migraine questionnaire
(DMQ3) [14] (Additional file 1) and an assessment of
disability associated with headaches experienced before
and during pregnancy by Migraine Disability Assessment
(MIDAS) Questionnaire [15]. In previous validation study,
using a physician-conducted interview as an empirical
index of validity, the deCODE Migraine Questionnaire
(DMQ3) diagnosed migraine with a sensitivity of 99%, a
specificity of 86% and a kappa statistic of 0.89 [16]. The
detailed migraine-specific questionnaire contained ques-
tions addressing age at migraine onset, physician diagnosis
of migraine, family history of migraine, details about
migraine attacks and medication used.
Headache classification was determined using the ICHD-
II criteria established by the International Headache Society
(IHS) [17]. “Definitive Migraine” (IHS category 1.1 or
1.2) was defined by at least five lifetime headacheattacks (criterion A) lasting 4–72 hours (criterion B),
with at least two of the qualifying pain characteristics
[unilateral location (criterion C1), pulsating quality (cri-
terion C2), moderate or severe pain intensity (criterion
C3), aggravation by routine physical exertion (criterion
C4)]; at least one of the associated symptoms [nausea
and/or vomiting (criterion D1), photo/phonophobia (cri-
terion D2)]; and not readily attributable to another central
nervous system disorder or head trauma (according to
subject self-report) (criterion E). “Probable Migraine” (IHS
category 1.6) was designated if all but one of the definitive
migraine criteria were fulfilled, excluding headaches
attributable to another disorder. Finally, any migraine
was defined as the group with either definitive migraine or
probable migraine combined.
The procedures used in the study were in agreement
with the protocol approved by the Institutional Review
Board of Swedish Medical Center (Swedish IRB # 008567).
All participants provided written informed consent.
Frequency distributions of sociodemographic, reproduct-
ive, medical and behavioral factors among groups de-
fined by ICHD-II (any migraine, no migraine) and the
cohort were compared using means (± standard devi-
ation (SD)) for continuous variables and counts and per-
centages for categorical variables. Bivariate differences
in characteristics associated with definitive and probable
migraine headaches were determined using Chi-square
test (or Fisher’s exact test) for categorical variables and
Student’s t-test for continuous variables.
The self-reported physician migraine diagnosis was com-
pared with the ICHD-II based diagnosis. The sensitivity
and specificity as well as positive predictive value and
negative predictive value of the self-reported diagnosis
were assessed. Concordance also was determined by
estimating the value of Cohen’s kappa coefficient [18].
All analyses were performed using Stata 9.0 (Stata, College
Station, TX) statistical analysis software. All reported
p-values are two-tailed. The 95% confidence interval (CI)
for the prevalence estimate of migraine was determined
using previously described methods [19].
Results
A total of 100 subjects met the ICHD-II criteria for
definitive migraine, and 49 additional subjects met the
criteria for probable migraine. The lifetime prevalence
of definitive migraine was 20.0% (95% CI 16.6-23.8%).
When probable migraine was included, the lifetime preva-
lence of migraine in this population increased to 29.8%
(95% CI 25.9-34.0%). However, chronic migraine, defined
as headache that occurs 15 or more days a month with
headache lasting 4 hours or longer for at least 3 con-
secutive months in individuals with current or prior
diagnosis of migraine, occurred only in 12 women out
of 149 ICHD-II diagnosed migraine cases.
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defined migraine status are presented in Table 1. A posi-
tive family history of migraine (defined as report of
migraine for at least one of the following relatives:
father, mother, sibling, grandparents, children) was re-
ported by 65.1% of participants with migraine and by
35.0% of individuals without migraine. Participants with
migraine tended to have higher pre-pregnancy body mass
index and were more likely to report a positive history
of chronic hypertension.
We confirmed self-reported migraine in 81.6% of women
when applying the ICHD-II criteria for definitive migraine
(63.1%) and probable migraine (18.5%) (Table 2). Overall,
when compared to the ICHD-II diagnosis, the self-reported
physician diagnosis had a sensitivity of 56.8% (95% CITable 1 Maternal characteristics of study population accordi
April 2009-Dec 2010, Seattle, WA
Characteristics Cohort
(N = 500)
Maternal Age (years) 33.4 ± 4.2
Maternal Age (years)
< 35 316 (63.2)
≥ 35 184 (36.8)
Maternal Race/Ethnicity
Non-Hispanic White 430 (86.0)
African American 8 (1.6)
Other 57 (11.4)
Missing 5 (1.0)
Annual Household Income ($)
<50,000 20 (4.0)
50,000-69,000 33 (6.6)
≥ 70,000 428 (85.6)
Missing 19 (3.8)
Single Marital Status 48 (9.6)
Nulliparous 261 (52.2)
Unplanned Pregnancy 72 (14.4)
Cigarette Smoker during early pregnancy 95 (19.0)
Family History of Headache/Migraine 220 (44.0)
History of Chronic Hypertension 11 (2.2)
Pre-Pregnancy Body Mass Index (kg/m2) 23.5 ± 4.7




≥ 30.0 42 (8.4)
Missing 2 (0.4)
Data in mean ± standard deviation (SD) or number (%).48.7%-64.5%); a specificity of 94.6% (95% CI 91.7%-96.5%)
and positive predictive value of 81.6% (95% CI 73.0%-
87.9%), as well as negative predictive value of 83.8%
(95% CI 79.8%-87.1%). Cohen’s kappa coefficient was
0.56. We did not observe differences in Choen’s kappa
coefficients when analyses were stratified by parity (i.e.,
nulliparous vs. multiparous). Characteristics such as nau-
sea and/or vomiting and photophobia were far more
prevalent among women who reported having a physician
diagnosis of migraine as compared with their counterparts
without such a diagnosis. Approximately 92% of women
reporting a diagnosis of migraine had the diagnosis
between the ages of 11 and 40 years (<10 years 6.8%;
11–20 years 38.8%; 21–30 years 42.7%; 31–40 years
10.7%; and >40 years 1.0%) (Figure 1).ng to ICHD-II criteria migraine (definitive + probable),
ICHD-II criteria for migraine (definitive + probable)
Yes (N = 149) No (N = 351) p-value
32.9 ± 4.4 33.6 ± 4.1 0.131
102 (68.5) 214 (61.0) 0.112
47 (31.5) 137 (39.0)
126 (84.6) 304 (86.6) 0.593
4 (2.7) 4 (1.1)
18 (12.1) 39 (11.1)
1 (0.7) 4 (1.1)
6 (4.0) 14 (4.0) 0.061
13 (8.7) 20 (5.7)
129 (86.6) 299 (85.2)
1 (0.7) 18 (5.1)
19 (12.8) 29 (8.3) 0.119
81 (54.4) 180 (51.3) 0.528
24 (16.1) 48 (13.7) 0.479
30 (20.1) 65 (18.5) 0.674
97 (65.1) 123 (35.0) <0.001
7 (4.7) 4 (1.1) 0.020
24.7 ± 5.4 23.0 ± 4.3 <0.001
5 (3.4) 19 (5.4) 0.012
89 (59.7) 251 (71.5)
34 (22.8) 58 (16.5)
20 (13.4) 22 (6.3)
1 (0.7) 1 (0.3)
Table 2 Summary of self-reported migraine and ICHD-II classified migraine
Characteristics Self-reported migraine
Yes No
(N = 103) (N = 395)
ICHD-II Diagnostic Criteria: Migraine
No 19 (18.5) 331 (83.8)
Yes 84 (81.6) 64 (16.2)
ICHD-II criteria migraine (probable) 19 (18.5) 29 (7.3)
ICHD-II criteria migraine (definitive) 65 (63.1) 35 (8.9)
Lifetime number of headache/migraine attacks ≥5 (criterion A) 95 (92.2) 94 (23.8)
Attacks lasting 4–72 hours (criterion B) 80 (77.7) 73 (18.5)
Unilateral headache location (criterion C1) 59 (57.3) 43 (10.9)
Pulsating pain quality (criterion C2) 62 (60.2) 60 (15.2)
Moderate or severe pain intensity (criterion C3) 95 (92.2) 101 (25.6)
Aggravation by routine physical activity (criterion C4) 72 (69.9) 70 (17.7)
Nausea and/or vomiting (criterion D1) 80 (77.7) 64 (16.2)
Photophobia 91 (88.4) 90 (22.8)
Phonophobia 86 (83.5) 79 (20.0)
Photo- and phonophobia (criterion D2) 82 (79.6) 66 (16.7)
2 subjects missing self-reported migraine information.
Data in number (%).
ICHD-II, International Classification of Headache Disorders, version 2 (ICHD-II).
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Our study finding of a high prevalence (29.8%) of mi-
graine in this cohort of pregnant women of reproductive
age is consistent with prior literature [3-5]. For example,
the American Migraine Prevalence and Prevention (AMPP)
Study found that the highest 1-year period prevalence
was observed among those ages 18–59. In that cohort,
17.1% of women met diagnostic criteria for definitive
migraine; and additional 5.1% met diagnostic criteria for
probable migraine [5]. Our study also showed good
agreement between self-reported migraine and ICHD-Figure 1 Frequency distribution and Kernel density plot of
maternal age at self-reported migraine diagnosis.II-based migraine classification. Our results were consistent
with reports by Schurks et al., who reported good agree-
ment between self-reported migraine and ICHD-II de-
fined migraine in a cohort of non-pregnant women [12].
Since migraine diagnosis relies on the presence of certain
symptoms as well as associated features, information that
can easily be obtained using questionnaires, the agreement
of such self-reports with the ICHD-II criteria is crucial for
studying migraine-specific characteristics in population-
based epidemiological studies.
The strengths of our study include the relatively large
number of women with information from the detailed
standardized questionnaire allowing us to apply all ICHD-
II criteria for migraine, and the opportunity to compare
with self-reported “physician-diagnosed” migraine infor-
mation. To our best knowledge, this is the first study
that investigated the agreement of self-reported migraine
with ICHD-II diagnosis in a pregnancy cohort. Pregnancy
is a unique condition. During the first trimester, women
experience increased physiological and psychological changes
such as hormonal surge and increased blood volume.
Lack of sleep, low blood sugar, dehydration and possible
caffeine withdrawal could also contribute to the occur-
rence of migraine attacks. The headache may be further
aggravated by stress [20,21]. In addition, there is a
heightened cautiousness among women with regards to
using medication during early pregnancy to prevent or
treat their headaches. Concurrently, most studies on
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of reported migraine attacks and pain intensity in the 2nd
and 3rd trimesters as hormone levels stabilize [22-24].
Some important limitations must be considered when
interpreting the results of our study. First, our ICHD-II-
diagnosed migraine is based on questionnaires adminis-
tered by trained interviewers instead of the gold standard
of physician examination. However, it is not feasible to
take implement full scale physical examinations with
medical histories in large epidemiological studies, mak-
ing our approach a practical alternative. In this study,
we observed good agreement between ICHD-II diagnosed
migraine and self-reported “physician diagnosed” migraine.
Secondly, misclassification of headache type is possible.
The questionnaire did not ask women to describe mul-
tiple headache types, and it is presumed that subjects
described the headache episodes most burdensome to
them. Misunderstanding one or more questions on the
migraine-specific questionnaire may also lead to a mis-
classification according to the ICHD-II criteria. Third,
caution must be taken that a diagnosis made during
pregnancy may be attributable to transient changes in
the characters of primitive headaches [25]; however, in
the current study, 93.3% of ICHD-II defined migraine
patients reported that their headache attacks started
more than one year before the interview, hence mitigat-
ing concern of misclassification in this case. Finally, in
this study, only a small minority of women with mi-
graine were classified as having chronic migraine per se.
Recall bias is possible although migraines are usually
dramatic events well remembered by the affected persons.
Conclusions
There is good agreement between self-reported physician-
diagnosed migraine and ICHD-II-based migraine classifi-
cation in this pregnancy cohort. Our findings demonstrate
the feasibility of using questionnaire-based migraine as-
sessment according to full ICHD-II criteria in epidemio-
logical studies of pregnant women.
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